Genmab | GEN - Sales Revenues


Genmab reported DKK1.06B in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Agios Pharmaceuticals USD 44.74M 25.94M Jun/2026
Almirall EUR 602.71M 55.09M Jun/2026
Amarin USD 49.22M 451K Dec/2025
Amgen USD 10.1B 1.48B Jun/2026
argenx SE USD 1.36B 240M Jun/2026
AstraZeneca USD 15.38B 90M Jun/2026
Bayer EUR 10.87B 2.54B Jun/2026
BioMarin Pharmaceutical USD 990M 224M Jun/2026
Demant DKK 6.25B 800M Dec/2025
Exelixis USD 628.69M 17.89M Jun/2026
Fresenius Medical Care EUR 4.86B 250M Jun/2026
Genmab DKK 1.06B 36M Dec/2025
GlaxoSmithKline GBP 8.41B 781M Jun/2026
GN Store Nord DKK 3.85B 830M Mar/2026
GRIFOLS EUR 1.87B 170M Jun/2026
Hikma Pharmaceutical USD 1.69B 863M Dec/2025
Insmed USD 425.49M 119.53M Jun/2026
Lakefront Biotherapeutics EUR 6.5M 894.32M Mar/2026
Lonza CHF 3.58B 63M Jun/2025
Merck EUR 5.13B 120M Mar/2026
Novartis USD 14.41B 1.3B Jun/2026
Regeneron Pharmaceuticals USD 4.29B 690M Jun/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
Sanofi EUR 11.95B 710M Jun/2026
UCB EUR 4.25B 764M Dec/2025